HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

December 06, 2023 00:29:56
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
COR2ED - Oncology Medical Conversation
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors

Dec 06 2023 | 00:29:56

/

Show Notes

In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unresectable HCC and explain the immunomodulation rationale to combine it with immune checkpoint inhibitor.

Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor.

Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option.

Other Episodes

Episode

April 15, 2025 00:21:27
Episode Cover

The HER2 Diagnostic and Treatment Landscape in NSCLC

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives  This is the first episode of a two-part series on the HER2 diagnostic...

Listen

Episode

December 06, 2023 00:29:42
Episode Cover

HCC: The role of immunotherapy beyond advanced HCC

In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional therapy for advanced...

Listen

Episode

May 28, 2024 00:21:16
Episode Cover

Regional differences in NET: Treatment and future developments

In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living...

Listen